Published in Medical Letter on the CDC and FDA, February 29th, 2004
CTI has an exclusive license to this patent property. Upon issuance, the U.S. patent will extend CTI's U.S. intellectual property position for Trisenox 11 years beyond the original orphan drug designation that currently expires in 2007.
The resulting patent will allow CTI to invest in label expansion studies in additional diseases, which could add significantly to the annual sales growth of the product. CTI markets...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA